Deyun Lu

Deyun Lu

Auto-generated profile, based on publicly available information

Deyun Lu

Shanghai Jiao Tong University School of Medicine

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 October 2021 in Molecular Genetics & Genomic Medicine
Verified
Journal Article
Open access
PDF file
YYYue Yu
Yue Yu
RSRuixue Shuai
Ruixue Shuai
LLLili Liang
Lili Liang
WQWenjuan Qiu
Wenjuan Qiu
LSLinghua Shen
Linghua Shen
LHLianshu Han
Lianshu Han
Background: To summarize the relationship between different MMUT gene mutations and the response to vitamin B12 in MMA.Methods: This was a retrospective study of patients diagnosed with mut‐type MMA. All patients with mut‐type MMA were tested for responsiveness to vitamin B12.Results: There were 81, 27, and 158 patients in the completely responsive, partially responsive, and nonresponsive groups, respectively, and the proportions of symptom occurrence were 30/81 (37.0%), 21/27 (77.8%), and 131/158 (82.9%), respectively (p < .001). The median levels of posttreatment propionyl carnitine (C3), C3/acetyl carnitine (C2) ratio in the blood, and methylmalonic acid in the urine were all lower than pretreatment, and the median level of C3/C2 ratio in the completely responsive group was within the normal range. In 266 patients, 144 different mutations in the MMUT gene were identified. Patients with the mutations of c.1663G>A, c.2080C>T, c.1880A>G, c.1208G>A, etc. were completely responsive and with the mutations of c.1741C>T, c.1630_1631GG>TA, c.599T>C, etc. were partially responsive. The proportions of healthy/developmental delay outcomes in the three groups were 63.0%/23.5%, 33.3%/40.7%, and 13.3%/60.1%, respectively (p < .001).Conclusion: Different mutations in the MMUT gene are associated with the effect of vitamin B12 treatment.

17 June 2023
Verified
Book Chapter
Closed access
PDF file
LLLili Liang
Lili Liang
RWRui-Fang Wang
Rui-Fang Wang
DLDe-Yun Lu
De-Yun Lu
YYYi Yang
Yi Yang
BXBing Xiao
Bing Xiao
WQWenjuan Qiu
Wenjuan Qiu

20 May 2020 in Research Square
Verified
Preprint
Open access
PDF file
DLDeyun Lu
Deyun Lu
FHFeng Han
Feng Han
WQWenjuan Qiu
Wenjuan Qiu
HZHuiwen Zhang
Huiwen Zhang
JYJun Ye
Jun Ye
LHLianshu Han
Lianshu Han
Background: This study aimed to describe the clinical and biochemical features of Chinese patients with ornithine transcarbamylase deficiency (OTCD), and to investigate the mutation spectrum of OTC gene and their potential correlation with phenotype.Methods: Sixty-nine patients with OTCD were enrolled between 2004 and 2019. Clinical and laboratory data were reviewed retrospectively from medical records. Results: Fifteen cases (13 males, 2 females) presented with early onset; 53 cases (21 males, 32 females) had late onset, and one female was asymptomatic. The median onset age was 1.5 years (range, 1 day-56 years). Urine orotic acid levels were increased in all patients tested, while only 47.6% of patients showed decreased serum levels of citrulline. The peak plasma ammonia levels were higher in early-onset patients than in late-onset patients (P < 0.01). Fifty-four different mutations of OTC gene were identified and 18 of them were novel. R277W (10.6%) was the most common mutation, followed by G195R (4.6%) and A209V (3.0%). By June 2019, 41 patients had survived, 24 were deceased, and 4 were lost to follow-up. Among the survivors, 13 patients had received liver transplantation at a median age of 3 years, with a one-year survival rate of 100%. The mortality of OTCD is extremely high among patients with early onset (80.0% versus 24.5% in patients with late onset).Conclusions: The evaluation of serum citrulline level is of limited value in diagnosis of OTCD, while urine orotic acid detection and genetic testing are more helpful.